A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Recruiting
Observational Study
Arthritis
Polymyalgia Rheumatica
Immune Checkpoint Inhibitors
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 20 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
The criteria are:
* Patients aged 18 years and above
* English (conversational level) speaking, with the ability to give informed consent
* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Exclusion Criteria
* …
Contacts